At a panel at CTO West Coast, experts from biopharmaceutical companies outlined innovative strategies to shape the future of ...

Mediar Therapeutics has dosed the first subject in the Phase II WISPer trial of its investigational therapy, MTX-463, for IPF ...

Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553 ...

Avenzo Therapeutics has commenced the open-label Phase I/II trial of its CDK4 selective inhibitor, AVZO-023, for breast ...

Halia Therapeutics has completed the enrolment in its Phase IIa trial of HT-6184 (Ofirnoflast) in those with lower-risk MDS.

US-based Iambic Therapeutics has concluded the dose escalation phase in its multi-centre Phase I/Ib trial of a ...

Moleculin Biotech has announced encouraging topline efficacy outcomes from its US Phase IB/II trial, MB-107, of Annamycin.

The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData.

Experts discuss the use of artificial intelligence (AI) and patient-centric strategies in oncology clinical trials.

Global Akeega sales will reach $676 million by 2030, while Talzenna and saruparib reach $618 million and $628 million ...